Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the migraine drug market will double from $2.86 billion in 2002 to approximately $5.6 billion in 2012 in the seven pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). The new Pharmacor study entitled Migraine also finds that the triptan drug class will hold 75% market share through 2012.

"Growth within the triptan class as a whole-which now includes seven marketed agents-and new formulations of currently marketed triptans, such as AstraZeneca's nasal formulation of zolmitriptan and GlaxoSmithKline's rapid- melt formulation of sumatriptan, will have the biggest market impact in the next ten years," said Tricia Nagle, analyst at Decision Resources. "The percentage of diagnosed and drug-treated patients in the seven markets who take triptans will increase from 25% in 2002 to just over 50% in 2012. The sheer number of triptans available in most markets by 2012 will boost their use because physicians will be able to choose from a variety of formulations."

Disease Facts-Migraine

In 2002 in the seven pharmaceutical markets, more than 74 million people suffered from migraine. Diagnosis rates for migraine remain low: up to 65% of afflicted persons in the major markets were undiagnosed in 2002. However, diagnosis rates have been increasing over the past decade as a result of campaigns by drug manufacturers and professional societies to increase awareness of the condition.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Migraine is a Cognos study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall for Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the Schizophrenia Market in 2012

View Now